“…uture”. See the discussion of Genentech I/Polypeptide expression (T 292/85) [1989] OJ EPO 275 in Biogen at page 48. Regeneron Pharmaceuticals, Inc v Kymab Ltd. [2018] EWCA Civ 671; [2018] RPC 14 is an example of this class of case. Thus, the objection of insufficiency is highly sensitive to the nature of the invention: see Kirin Amgen at…”
“…On 28 March 2018 we gave judgment upon the substantive appeal: [2018] EWCA Civ 671. The parties have not been able to agree a form of order, however. A number of issues remain in dispute. Pursuant to our directions, the parties have now filed…”